Changsha, China – 15 Sep 2026 – The Hunan Provincial Medical Products Administration (Hunan MPA) announced that, effective 15 September 2026, it is granting its first authorization to the Hunan Xiangjiang New Area Drug Evaluation and Verification Center (Hunan Provincial MPA Evaluation and Verification Xiangjiang New Area Branch Center) to handle 6 review items, 7 verification items and 2 supervisory inspection items covering drugs, medical devices and cosmetics within the Xiangjiang New Area, with the scope of devolved authority to be dynamically adjusted based on the branch center’s capability.
Authorization Snapshot
| Item | Detail |
|---|---|
| Authority | Hunan Provincial Medical Products Administration (Hunan MPA), China |
| Action | First delegation of review, verification and inspection authority to a New Area branch center |
| Recipient | Hunan Xiangjiang New Area Drug Evaluation and Verification Center (Hunan MPA Evaluation and Verification Xiangjiang New Area Branch Center) |
| Effective Date | 15 September 2026 |
| Delegated Scope | 6 review items, 7 verification items, 2 supervisory inspection items – covering drugs, medical devices and cosmetics within the Xiangjiang New Area |
| Policy Basis | State Council General Office Document 〔2024〕 No. 53 – Opinions on Comprehensively Deepening Drug and Medical Device Regulatory Reform to Promote High‑Quality Development of the Pharmaceutical Industry |
| Adjustment Mechanism | Dynamic adjustment of delegated items based on the branch center’s review and verification capability |
| Original Announcement | mpa.hunan.gov.cn (published 16 September 2026) |
Authorization Details & Governance
- Full Itemized List: The annex — Catalogue of First‑Batch Authorized Items of the Xiangjiang New Area Branch Center — enumerates each delegated matter across review (6), verification (7) and supervisory inspection (2); individual item specifications were not disclosed in the announcement text itself.
- Three‑Product Coverage: The devolved authority spans drugs, medical devices and cosmetics, giving companies in the New Area a single local channel for these regulatory interactions.
- Capability‑Linked Devolution: The Hunan MPA will dynamically adjust the authorized scope in line with the branch center’s demonstrated review and verification capacity — a built‑in performance gate rather than a one‑off transfer.
- Reform Context: The move implements Document 〔2024〕 No. 53, which directs deeper review‑and‑approval system reform and higher regulatory efficiency as levers for high‑quality pharmaceutical industry development.
Sector Background
- Decentralization Trend: Provincial MPAs have progressively devolved technical review and on‑site inspection functions to regional centers, mirroring the national NMPA reform agenda of shortening approval pathways while retaining oversight.
- Xiangjiang New Area: Established in 2015 as a national‑level new area, the zone hosts Changsha’s biomedical and life‑sciences cluster, with dedicated industrial parks attracting drug, device and cosmetics manufacturers seeking proximity to regulators.
- Branch‑Center Model: Setting up an evaluation and verification branch inside an industrial park places regulatory capacity next to industry — a model previously piloted in other Chinese provinces’ development zones.
Market Impact & Outlook
- Faster Local Processing: Companies headquartered or operating in the Xiangjiang New Area can expect shorter turnaround for the delegated review, verification and inspection matters without routing through the provincial capital’s central queue.
- Investment Signal: On‑site regulatory capacity is a tangible incentive for life‑sciences investment decisions, strengthening the New Area’s bid to attract drug, device and cosmetics projects.
- Scalable Precedent: The dynamic adjustment clause signals that the delegated catalogue may expand as the branch matures — worth monitoring for sponsors planning Hunan registrations or site relocations.
- Compliance Posture: Manufacturers in the zone should map their pending and planned regulatory interactions against the 15 authorized items to determine which now run through the branch center versus the provincial MPA.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the scope, timing and evolution of regulatory authority delegated to the Xiangjiang New Area Branch Center. The authorized item list remains subject to dynamic adjustment by the Hunan MPA, and actual review timelines, scope changes and regulatory outcomes may differ materially from current expectations.-China Health Reform Pulse
Policy Source: http://mpa.hunan.gov.cn/mpa/xxgk/tzgg/wjtz/202609/t20260916_34065635.html